跳到正文
原文
STAT 主站· Katie Palmer·· 29 天前AI 评分51

远程医疗平台在未获FDA批准前推广GLP-1处方治疗成瘾

STAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction

AI 导读

几家专注成瘾治疗的远程医疗公司开始推广非适应症处方GLP-1药物(包括品牌药和复配药)用于治疗酒精使用障碍和其他成瘾。专家警告称,这种做法将非批准药物的验证负担转移给了患者。

正文

Online platforms, experts say, can shift the burden of vetting unapproved drugs on to patients

GLP-1 prescriptions in a fridge at Caron Treatment Centers in Wernersville, Pa., where providers have prescribed GLP-1s to more than 650 patients with substance use disorders.Rachel Wisniewski for STAT

Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag of clinical AI, digital health at the FDA, and the boom in direct-to-consumer telehealth. Confidential tips can be sent on Signal at palmer.01.

For the popular diabetes and obesity medications known as GLP-1s, addiction medicine is one of many possible promising next acts.

Eli Lilly is investigating a new drug, brenipatide, and testing it in alcohol use disorder. A new company called Baseline Therapeutics is studying a GLP-1 receptor agonist in alcohol, cocaine, and methamphetamine use disorders; Altimmune is testing one called pemvidutide for alcohol. Addiction medicine specialists are hopeful that the Food and Drug Administration may soon approve a new medication for alcohol use disorder — the first in two decades. 

But some telehealth platforms that specialize in treating addiction aren’t waiting. In the last year, a few companies have begun to market off-label prescriptions of GLP-1s, both branded and compounded, to treat alcohol use disorder and other addictions. 

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

  1. Health Tech Correspondent

    Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag of clinical AI, digital health at the FDA, and the boom in direct-to-consumer telehealth. Confidential tips can be sent on Signal at palmer.01.

来源:STAT 主站 · statnews.com